MedTrace Logo

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

NCT00282828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 397

Last updated 2013-10-14

Study results available
· View outcomes & findings →

Summary

This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.

Conditions

  • Social Phobia

Interventions

DRUG

Sertraline

DRUG

Venlafaxine

DRUG

Placebo

DRUG

Clonazepam

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Mark H. Pollack, MD · Massachusetts General Hospital

  • Murray B. Stein, MD, MPH · University of California San Deigo

  • Michael Van Ameringen, MD, FRCPC · Anxiety Disorders Clinic McMaster University Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282828 on ClinicalTrials.gov